Genomic insights into human cortical development and neurodevelopmental disease

  • Life Sciences
Speaker Arnold Kriegstein, M.D., Ph.D.
University of California, San Francisco
Date & Time


Location

Gerald D. Fischbach Auditorium
160 5th Avenue
New York, NY 10010 United States

Life Sciences

Life Sciences lectures bring together scientists and scholars to discuss diverse topics related to fundamental questions in biology. The lectures are open to the public and are held at the Gerald D. Fischbach Auditorium at the Simons Foundation headquarters in New York City. Tea is served prior to each lecture.

Video Thumbnail

By clicking to watch this video, you agree to our privacy policy.

On 1 February 2017, Arnold Kriegstein described recent advances in our understanding of the unique features of human cortical development and discussed insights into the origins of neurodevelopmental disorders.

His talk was part of the Simons Foundation Life Sciences lecture series.

About the Lecture

The developing human cortex contains a massively expanded outer subventricular zone, not found in rodents, that contains neural progenitor cells responsible for an evolutionary increase in cortical size and complexity. Transcriptome profiling of these cells has provided a novel model of primate corticogenesis and provided insights into lissencephaly (smooth brain syndrome) and microcephaly (smaller than normal brain size).

In this lecture, Arnold Kriegstein described recent advances in our understanding of the unique features of human cortical development. He also highlighted an evolutionary increase in the number of a specific subtype of neural stem cell, oRG cells, which in concert with their transit amplifying daughter cells, contributed to increased cortical size and complexity of the human brain. In addition, he discussed how mRNA sequencing of single human progenitor cells and immature cortical neurons led to a novel model of human cortical development and provided insights into the origins of neurodevelopmental disease.

About the Speaker

Arnold Kriegstein received his B.A. from Yale University and his M.D. and Ph.D. from New York University in 1977. He completed residency training in neurology at Harvard University and is a board-certified neurologist. He has held academic appointments at Stanford, Yale and Columbia. In 2004, he became the founding director of the Broad Stem Cell Center at the University of California, San Francisco. His research focuses on development of the embryonic human and mouse brain.

Past Lectures

What do we mean by ‘autism risk genes’?

David Ledbetter, Ph.D.
Chief Clinical Officer, Dascena

Joseph Buxbaum, Ph.D.
Director, Seaver Autism Center
Professor, Psychiatry, Neuroscience, Genetics and Genomic Sciences
Vice Chair for Research and Vice Chair for Mentoring, Psychiatry, Icahn School of Medicine at Mount Sinai

Heather Mefford, M.D., Ph.D.
Full Member, St. Jude Children’s Research Hospital

David Ledbetter and Joseph Buxbaum discussed whether there are genes for which mutations confer risk specific to autism or whether these genes are really conferring general risk of disrupted brain development. The discussion was moderated by Heather Mefford.

Small molecules, genes and antisense oligonucleotides: Industry perspectives on treatment development for ASD

Federico Bolognani, M.D., Ph.D.
Vice President, Head of Clinical Science, Axial Therapeutics

Stuart Cobb, Ph.D.
Chief Scientific Officer, Neurogene; Research Fellow, University of Edinburgh

Yael Weiss, M.D., Ph.D.
Vice President, Business Development, Ultragenyx

Randy Carpenter, M.D.
Chief Medical Officer, Rett Syndrome Research Trust; Co-Founder, Allos Pharma

Federico Bolognani, Stuart Cobb, and Yael Weiss joined a panel to discuss new industry developments on the use of small molecules, gene therapy and antisense oligonucleotides as treatment approaches for autism spectrum disorders (ASD). The panel discussion was moderated by Randall Carpenter.

New research results from the Australian Autism Biobank study

Jake Gratten, Ph.D.Group Leader, Mater Research Institute, The University of Queensland
Adjunct Senior Research Fellow, Institute for Molecular Bioscience
Naomi Wray, Ph.D.National Health and Medical Research Council Leadership Fellow – Group Leader, Institute for Molecular Bioscience
Affiliate Professor, Queensland Brain Institute, The University of Queensland

Jake Gratten and Naomi Wray presented findings from the Australian Autism Biobank study, an initiative to establish an Australian resource of biospecimens, phenotypes and genomic data for autism research.

Subscribe to our newsletter and receive SFARI funding announcements and news